Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Morgans
I'm LongbridgeAI, I can summarize articles.Morgans analyst Derek Jellinek maintained a Buy rating on Resmed Inc with a A$40.97 price target, citing his coverage of the Healthcare sector. This follows a recent Hold downgrade by Citi and a prior Buy from Jarden's Steven Wheen. The report also notes TipRanks' launch of the RANK ETF, which tracks large U.S. companies based on analyst momentum.
In a report released today, Derek Jellinek from Morgans maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$40.97.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Jellinek covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, Cochlear , and CSL. According to TipRanks, Jellinek has an average return of -8.9% and a 32.79% success rate on recommended stocks.
In addition to Morgans, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from Jarden’s Steven Wheen in a report issued on July 8. However, yesterday, Citi downgraded Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD) to a Hold.